JPS5925329A - インタ−フエロン誘起剤 - Google Patents
インタ−フエロン誘起剤Info
- Publication number
- JPS5925329A JPS5925329A JP57133073A JP13307382A JPS5925329A JP S5925329 A JPS5925329 A JP S5925329A JP 57133073 A JP57133073 A JP 57133073A JP 13307382 A JP13307382 A JP 13307382A JP S5925329 A JPS5925329 A JP S5925329A
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- agent
- activity
- interferon
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002799 interferon inducing agent Substances 0.000 title claims abstract 3
- 150000004676 glycans Chemical class 0.000 claims abstract description 6
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 6
- 239000005017 polysaccharide Substances 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 108010050904 Interferons Proteins 0.000 abstract description 6
- 102000014150 Interferons Human genes 0.000 abstract description 6
- 229940079322 interferon Drugs 0.000 abstract description 6
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 208000035473 Communicable disease Diseases 0.000 abstract description 3
- 230000000840 anti-viral effect Effects 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 238000002523 gelfiltration Methods 0.000 abstract description 2
- 230000004043 responsiveness Effects 0.000 abstract description 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000700647 Variola virus Species 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- -1 hard horns Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000115 helium ionisation detection Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57133073A JPS5925329A (ja) | 1982-07-30 | 1982-07-30 | インタ−フエロン誘起剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57133073A JPS5925329A (ja) | 1982-07-30 | 1982-07-30 | インタ−フエロン誘起剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5925329A true JPS5925329A (ja) | 1984-02-09 |
| JPH039882B2 JPH039882B2 (enrdf_load_stackoverflow) | 1991-02-12 |
Family
ID=15096209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57133073A Granted JPS5925329A (ja) | 1982-07-30 | 1982-07-30 | インタ−フエロン誘起剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5925329A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749831A (en) * | 1984-12-20 | 1988-06-07 | Mitsubishi Denki Kabushiki Kaisha | Dead tank type gas circuit breaker |
| US4900815A (en) * | 1986-05-23 | 1990-02-13 | Daiichi Seiyaku Co., Ltd. | Sulfated polysaccharide DS4152 |
-
1982
- 1982-07-30 JP JP57133073A patent/JPS5925329A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749831A (en) * | 1984-12-20 | 1988-06-07 | Mitsubishi Denki Kabushiki Kaisha | Dead tank type gas circuit breaker |
| US4900815A (en) * | 1986-05-23 | 1990-02-13 | Daiichi Seiyaku Co., Ltd. | Sulfated polysaccharide DS4152 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH039882B2 (enrdf_load_stackoverflow) | 1991-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3789239T2 (de) | Pharmazeutische Zusammensetzung enthaltend Interferon für bukkale Verabreichung. | |
| KR100643553B1 (ko) | 백혈구 수를 증진시키기 위한 약제학적 조성물 | |
| Hilleman | Prospects for the use of double-stranded ribonucleic acid (poly I: C) inducers in man | |
| EP0809996A2 (en) | Interferon conjugates | |
| JPS62240627A (ja) | ウイルス性および癌性の皮膚傷害等の治療のための組成物および該組成物を用いる方法 | |
| Uno et al. | Direct and indirect effects of interferon on in vivo murine tumor cell growth | |
| STRINGFELLOW et al. | Interferon induction by 5-halo-6-phenyl pyrimidinones | |
| EP0382551B1 (en) | Prevention and treatment of herpes virus infections | |
| Brunda et al. | The anti‐tumor effect of recombinant interferon alpha or gamma is influenced by tumor location | |
| CN1090506C (zh) | 溶菌酶二聚体的新应用 | |
| JP3150967B2 (ja) | 二本鎖ｒｎａによる損傷に続くショックからの保護 | |
| Degré | Influence of exogenous interferon on the peripheral white blood cell count in mice | |
| JPS5925329A (ja) | インタ−フエロン誘起剤 | |
| De Maeyer et al. | Delayed hypersensitivity to Newcastle disease virus in high and low interferon-producing mice. | |
| JPH10504279A (ja) | ウイルス感染症及び場合により炎症の予防及び／又は治療用医薬組成物並びにそれらの治療方法 | |
| JP2938916B2 (ja) | ヘルペスウィルスの増殖阻害および潜伏感染後の再発阻止剤 | |
| RU2233171C2 (ru) | ПОЛИФУНКЦИОНАЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ L-ЛИЗИН-α-ОКСИДАЗЫ ИЗ ГРИБА РОДА TRICHODERMA И СПОСОБ ПОЛУЧЕНИЯ ЭТОГО ФЕРМЕНТА | |
| Park et al. | Prophylaxis of herpetic keratoconjunctivitis with interferon inducers: Preliminary observations | |
| DE102011003478A1 (de) | Antivirales Mittel enthaltend rekombinante Mistellektine | |
| KR960011231B1 (ko) | 인체 백혈구 인터페론 및 침투 향상제를 함유하는 피부 병변 치료용 국소 조성물 | |
| JP3040711B2 (ja) | 抗腫瘍剤及びその製造法 | |
| JP2007505128A (ja) | 造血を高める方法 | |
| JP4781624B2 (ja) | Ｒａｎｔｅｓ誘導剤 | |
| EP0344643A2 (en) | Antiviral pharmaceutical composition | |
| SU897099A3 (ru) | Способ получени вещества кS-2-а,обладающего противоопухолевым и антимикробным действием |